SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : IDPH--Positive preliminary results for pivotal trial of ID

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Webhead who wrote (364)2/13/1997 2:11:00 PM
From: I. Luttichuys   of 1762
 
Hello ECG, Thank you for the interesting post. I had not heard of this patent. HMMMMM... I am sitting here unsure of the significance of this as well. I am curious as to where it might fit into IDEC's current portfolio. It doesn't necessarily mean much but, I am not aware of who might be working on or who might already possess such an approach. It seems there would be many benefits to an induced T-lymphocyte response in general and I am left wondering whether this could be used in conjunction with other IDEC therapies already extant. I would like to find out more about this.
There is increased call activity on IDEC stock. I picked up a little more at about 21 1/4 today. They're giving it away these days. Anyway, my thinking is that IDEC will move as earnings approach. I am also speculating that we may have some extra news in earnings relating to recent and near-term forward-looking events. A lot has happened recently and I am gambling on a little recognition of this fact soon. I know many biotechs with many interesting things on the burner but few as attractive with respect to how the timing looks as this one nor, for that matter, are they quite as interesting. We shall see...
Looking forward to your further finds,
BENNETT
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext